Vanguard Group
NBSE icon

Vanguard Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Vanguard Group’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,981
Closed -$8.54K – 4484
2024
Q1 		$8.54K Hold
18,981
– – ﹤0.01% 4432
2023
Q4 		$14K Hold
18,981
– – ﹤0.01% 4465
2023
Q3 		$16.5K Hold
18,981
– – ﹤0.01% 4508
2023
Q2 		$35.5K Buy
18,981
+143
+0.8% +$471 ﹤0.01% 4491
2023
Q1 		$69.7K Sell
18,838
-28,446
-60% -$131K ﹤0.01% 4435
2022
Q4 		$180K Sell
47,284
-5,669
-11% -$29.1K ﹤0.01% 4327
2022
Q3 		$419K Hold
52,953
– – ﹤0.01% 4262
2022
Q2 		$1.11M Hold
52,953
– – ﹤0.01% 4052
2022
Q1 		$1.99M Sell
52,953
-15,279
-22% -$528K ﹤0.01% 3960
2021
Q4 		$3.83M Sell
68,232
-85
-0.1% -$5.71K ﹤0.01% 3758
2021
Q3 		$4.93M Buy
68,317
+3,425
+5% +$262K ﹤0.01% 3671
2021
Q2 		$6.22M Buy
64,892
+16,950
+35% +$1.87M ﹤0.01% 3476
2021
Q1 		$7.09M Buy
47,942
+1,697
+4% +$308K ﹤0.01% 3350
2020
Q4 		$6.46M Buy
46,245
+417
+0.9% +$67.6K ﹤0.01% 3221
2020
Q3 		$6.96M Buy
45,828
+39,399
+613% +$6.43M ﹤0.01% 2982
2020
Q2 		$1.13M Buy
6,429
+4,374
+213% +$732K ﹤0.01% 3581
2020
Q1 		$293K Hold
2,055
– – ﹤0.01% 3796
2019
Q4 		$296K Hold
2,055
– – ﹤0.01% 3881
2019
Q3 		$205K Buy
2,055
+725
+55% +$71.6K ﹤0.01% 3958
2019
Q2 		$91K Hold
1,330
– – ﹤0.01% 4059
2019
Q1 		$60K Hold
1,330
– – ﹤0.01% 4051
2018
Q4 		$46K Sell
1,330
-3,402
-72% -$246K ﹤0.01% 4078
2018
Q3 		$350K Hold
4,732
– – ﹤0.01% 3909
2018
Q2 		$371K Sell
4,732
-89
-2% -$7.77K ﹤0.01% 3876
2018
Q1 		$424K Buy
4,821
+742
+18% +$110K ﹤0.01% 3817
2017
Q4 		$3.04M Buy
4,079
+1,258
+45% +$486K ﹤0.01% 3301
2017
Q3 		$812K Buy
2,821
+790
+39% +$216K ﹤0.01% 3642
2017
Q2 		$520K Buy
2,031
+14
+0.7% +$3.76K ﹤0.01% 3720
2017
Q1 		$670K Buy
2,017
+59
+3% +$27.3K ﹤0.01% 3687
2016
Q4 		$1.18M Sell
1,958
-349
-15% -$369K ﹤0.01% 3511
2016
Q3 		$2.61M Hold
2,307
– – ﹤0.01% 3294
2016
Q2 		$2.53M Buy
2,307
+25
+1% +$31.4K ﹤0.01% 3286
2016
Q1 		$2.93M Buy
2,282
+279
+14% +$398K ﹤0.01% 3220
2015
Q4 		$4.92M Buy
2,003
+191
+11% +$293K ﹤0.01% 2991
2015
Q3 		$2M Buy
1,812
+273
+18% +$316K ﹤0.01% 3376
2015
Q2 		$1.54M Buy
1,539
+17
+1% +$18.3K ﹤0.01% 3520
2015
Q1 		$1.55M Buy
1,522
+121
+9% +$399K ﹤0.01% 3498
2014
Q4 		$4.67M Buy
1,401
+42
+3% +$129K ﹤0.01% 2934
2014
Q3 		$3.94M Buy
1,359
+113
+9% +$374K ﹤0.01% 2959
2014
Q2 		$4.74M Buy
1,246
+401
+47% +$1.51M ﹤0.01% 2861
2014
Q1 		$4.6M Buy
845
+677
+403% +$3.57M ﹤0.01% 2867
2013
Q4 		$529K Buy
168
+138
+460% +$426K ﹤0.01% 3580
2013
Q3 		$97K Buy
+30
New +$81.8K ﹤0.01% 3774

Other funds holding NBSE

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Vanguard Group's NBSE Position: Q2 2024 in Review

Vanguard Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 18,981 shares — an estimated $8.54K sold.

Vanguard Group first reported a position in NBSE in Q3 2013 and held it in 43 quarters. The position peaked at $7.09M in Q1 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

  • Vanguard Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 18,981 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $8.54K.
  • Vanguard Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2013 and held it in 43 quarters.
  • Vanguard Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $7.09M in Q1 2021.
  • 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.